MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells

Venumadhav Janganati, Jessica Ponder, Meenakshisundaram Balasubramaniam, Poornima Bhat-Nakshatri, Eli E. Bar, Harikrishna Nakshatri, Craig T. Jordan, Peter A. Crooks

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Triazole derivatives of melampomagnolide B (MMB) have been synthesized via click chemistry methodologies and screened against a panel of 60 human cancer cell lines. Several derivatives showed promising anti-cancer activity, affording growth inhibition (GI50) values in the nanomolar range (GI50 = 0.02–0.99 μM). Lead compound 7h exhibited EC50 values of 400 nM and 700 nM, respectively, against two AML clinical specimens. Compound 7h was significantly more potent than parthenolide as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its ability to inhibit the NF-κB pathway. In TMD-231 breast cancer cells, treatment with 7h reduced DNA binding activity of NF-κB through inhibition of IKK-β mediated p65 phosphorylation and caused elevation of basal IκBα levels through inhibition of constitutive IκBα turnover and NF-κB activation. Molecular docking and dynamic modeling studies indicated that 7h interacts with the kinase domain of the monomeric IKKβ subunit, leading to inhibition of IKKβ activation, and compromising phosphorylation of downstream targets of the NF-κB pathway; dynamic modeling studies show that this interaction also causes unwinding of the α-helix of the NEMO binding site on IKKβ. Molecular docking studies with 10, a water-soluble analog of 7h, demonstrate that this analog interacts with the dimerization/oligomerization domain of monomeric IKKβ and may inhibit oligomer formation and subsequent autophosphorylation. Sesquiterpene lactones 7h and 10 are considered ideal candidates for potential clinical development.

Original languageEnglish (US)
Pages (from-to)562-581
Number of pages20
JournalEuropean Journal of Medicinal Chemistry
Volume157
DOIs
StatePublished - Sep 5 2018

Fingerprint

Phosphorylation
Triazoles
Tumors
Cells
Chemical activation
Click Chemistry
Lead compounds
Derivatives
Neoplasms
Oligomerization
Dimerization
Sesquiterpenes
Lactones
Molecular Dynamics Simulation
Tumor Cell Line
Oligomers
Phosphotransferases
Binding Sites
Breast Neoplasms
Cell Line

Keywords

  • Click chemistry
  • Leukemia cell lines
  • Melampomagnolide B
  • NF-κB pathway
  • Triazole derivatives

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells. / Janganati, Venumadhav; Ponder, Jessica; Balasubramaniam, Meenakshisundaram; Bhat-Nakshatri, Poornima; Bar, Eli E.; Nakshatri, Harikrishna; Jordan, Craig T.; Crooks, Peter A.

In: European Journal of Medicinal Chemistry, Vol. 157, 05.09.2018, p. 562-581.

Research output: Contribution to journalArticle

Janganati, Venumadhav ; Ponder, Jessica ; Balasubramaniam, Meenakshisundaram ; Bhat-Nakshatri, Poornima ; Bar, Eli E. ; Nakshatri, Harikrishna ; Jordan, Craig T. ; Crooks, Peter A. / MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 157. pp. 562-581.
@article{d0d9c464bf8d4e3a856be0b1720f1c58,
title = "MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells",
abstract = "Triazole derivatives of melampomagnolide B (MMB) have been synthesized via click chemistry methodologies and screened against a panel of 60 human cancer cell lines. Several derivatives showed promising anti-cancer activity, affording growth inhibition (GI50) values in the nanomolar range (GI50 = 0.02–0.99 μM). Lead compound 7h exhibited EC50 values of 400 nM and 700 nM, respectively, against two AML clinical specimens. Compound 7h was significantly more potent than parthenolide as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its ability to inhibit the NF-κB pathway. In TMD-231 breast cancer cells, treatment with 7h reduced DNA binding activity of NF-κB through inhibition of IKK-β mediated p65 phosphorylation and caused elevation of basal IκBα levels through inhibition of constitutive IκBα turnover and NF-κB activation. Molecular docking and dynamic modeling studies indicated that 7h interacts with the kinase domain of the monomeric IKKβ subunit, leading to inhibition of IKKβ activation, and compromising phosphorylation of downstream targets of the NF-κB pathway; dynamic modeling studies show that this interaction also causes unwinding of the α-helix of the NEMO binding site on IKKβ. Molecular docking studies with 10, a water-soluble analog of 7h, demonstrate that this analog interacts with the dimerization/oligomerization domain of monomeric IKKβ and may inhibit oligomer formation and subsequent autophosphorylation. Sesquiterpene lactones 7h and 10 are considered ideal candidates for potential clinical development.",
keywords = "Click chemistry, Leukemia cell lines, Melampomagnolide B, NF-κB pathway, Triazole derivatives",
author = "Venumadhav Janganati and Jessica Ponder and Meenakshisundaram Balasubramaniam and Poornima Bhat-Nakshatri and Bar, {Eli E.} and Harikrishna Nakshatri and Jordan, {Craig T.} and Crooks, {Peter A.}",
year = "2018",
month = "9",
day = "5",
doi = "10.1016/j.ejmech.2018.08.010",
language = "English (US)",
volume = "157",
pages = "562--581",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells

AU - Janganati, Venumadhav

AU - Ponder, Jessica

AU - Balasubramaniam, Meenakshisundaram

AU - Bhat-Nakshatri, Poornima

AU - Bar, Eli E.

AU - Nakshatri, Harikrishna

AU - Jordan, Craig T.

AU - Crooks, Peter A.

PY - 2018/9/5

Y1 - 2018/9/5

N2 - Triazole derivatives of melampomagnolide B (MMB) have been synthesized via click chemistry methodologies and screened against a panel of 60 human cancer cell lines. Several derivatives showed promising anti-cancer activity, affording growth inhibition (GI50) values in the nanomolar range (GI50 = 0.02–0.99 μM). Lead compound 7h exhibited EC50 values of 400 nM and 700 nM, respectively, against two AML clinical specimens. Compound 7h was significantly more potent than parthenolide as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its ability to inhibit the NF-κB pathway. In TMD-231 breast cancer cells, treatment with 7h reduced DNA binding activity of NF-κB through inhibition of IKK-β mediated p65 phosphorylation and caused elevation of basal IκBα levels through inhibition of constitutive IκBα turnover and NF-κB activation. Molecular docking and dynamic modeling studies indicated that 7h interacts with the kinase domain of the monomeric IKKβ subunit, leading to inhibition of IKKβ activation, and compromising phosphorylation of downstream targets of the NF-κB pathway; dynamic modeling studies show that this interaction also causes unwinding of the α-helix of the NEMO binding site on IKKβ. Molecular docking studies with 10, a water-soluble analog of 7h, demonstrate that this analog interacts with the dimerization/oligomerization domain of monomeric IKKβ and may inhibit oligomer formation and subsequent autophosphorylation. Sesquiterpene lactones 7h and 10 are considered ideal candidates for potential clinical development.

AB - Triazole derivatives of melampomagnolide B (MMB) have been synthesized via click chemistry methodologies and screened against a panel of 60 human cancer cell lines. Several derivatives showed promising anti-cancer activity, affording growth inhibition (GI50) values in the nanomolar range (GI50 = 0.02–0.99 μM). Lead compound 7h exhibited EC50 values of 400 nM and 700 nM, respectively, against two AML clinical specimens. Compound 7h was significantly more potent than parthenolide as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its ability to inhibit the NF-κB pathway. In TMD-231 breast cancer cells, treatment with 7h reduced DNA binding activity of NF-κB through inhibition of IKK-β mediated p65 phosphorylation and caused elevation of basal IκBα levels through inhibition of constitutive IκBα turnover and NF-κB activation. Molecular docking and dynamic modeling studies indicated that 7h interacts with the kinase domain of the monomeric IKKβ subunit, leading to inhibition of IKKβ activation, and compromising phosphorylation of downstream targets of the NF-κB pathway; dynamic modeling studies show that this interaction also causes unwinding of the α-helix of the NEMO binding site on IKKβ. Molecular docking studies with 10, a water-soluble analog of 7h, demonstrate that this analog interacts with the dimerization/oligomerization domain of monomeric IKKβ and may inhibit oligomer formation and subsequent autophosphorylation. Sesquiterpene lactones 7h and 10 are considered ideal candidates for potential clinical development.

KW - Click chemistry

KW - Leukemia cell lines

KW - Melampomagnolide B

KW - NF-κB pathway

KW - Triazole derivatives

UR - http://www.scopus.com/inward/record.url?scp=85051535197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051535197&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.08.010

DO - 10.1016/j.ejmech.2018.08.010

M3 - Article

C2 - 30121494

AN - SCOPUS:85051535197

VL - 157

SP - 562

EP - 581

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -